STX209

DRUG3 trials

Sponsors

Seaside Therapeutics, Inc.

Conditions

Fragile X Syndrome

Phase 2

Safety, Tolerability and Efficacy Study of STX209 in Subjects With Fragile X Syndrome

CompletedNCT00788073

Seaside Therapeutics, Inc.Fragile X Syndrome

Start: 2008-11-30End: 2010-05-31Updated: 2013-05-06

Unknown Phase

Biomarker Testing and DNA Collection in Subjects Participating in Protocol 22001

CompletedNCT00823368

Seaside Therapeutics, Inc.Fragile X Syndrome

Start: 2009-01-31Updated: 2013-07-31

Biomarker and DNA Collection in Subjects Participating in Protocol 22003

CompletedNCT00892580

Seaside Therapeutics, Inc.Fragile X Syndrome

Start: 2009-05-31Updated: 2013-07-31